Dr. Matthew C. Cave, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 124
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Kentucky College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
KY license 38459 -
Hepatology Physician
KY license 38459 -
Internal Medicine Physician
KY license 38459 -
Transplant Hepatology Physician
KY license 38459
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- Baptist Health Hardin Elizabethtown, KY
- Baptist Health Lagrange La Grange, KY
- University of Louisville Hospital Louisville, KY
Medical groups
- University of Louisville Physicians Inc (1,445 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 267
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 98 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 68 | 51 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 35 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 34 | 28 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Louisville, KY | 60 |
| Xifaxan (rifaximin) Other prescribers in Louisville, KY | 44 |
| Furosemide Other prescribers in Louisville, KY | 38 |
| Ursodiol Other prescribers in Louisville, KY | 37 |
| Pantoprazole Sodium Other prescribers in Louisville, KY | 36 |
| Spironolactone Other prescribers in Louisville, KY | 35 |
| Azathioprine Other prescribers in Louisville, KY | 33 |
| Pentoxifylline Other prescribers in Louisville, KY | 28 |
| Ozempic (semaglutide) Other prescribers in Louisville, KY | 26 |
| Entecavir | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 89 payments worth $106,635 in total to this clinician.
| Novo Nordisk Inc | $42,515 |
|---|---|
| Intercept Pharmaceuticals, Inc. | $20,584 |
| Madrigal Pharmaceuticals | $20,126 |
| Gilead Sciences, Inc. | $13,708 |
| Ipsen Biopharmaceuticals, Inc | $9,673 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.37 |
| Compensation for services other than consulting (speaking, faculty) | $78,926 |
|---|---|
| Speaking at a medical education program | $12,400 |
| Travel and Lodging | $7,517 |
| Consulting Fee | $5,580 |
| Food and Beverage | $2,212 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,127 |
| Novo Nordisk Inc Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $8,046 |
| Novo Nordisk Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,654 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,869 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $5,580 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Novo Nordisk Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,103 |
| Ipsen Biopharmaceuticals, Inc Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Intercept Pharmaceuticals, Inc. Jul 15, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $4,960 |
| Madrigal Pharmaceuticals Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
All 41 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Novo Nordisk Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,103 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,869 |
| Novo Nordisk Inc Nov 13, 2025 | Travel and Lodging Wegovy · Obesity · travel to Lexington, KY · in-kind | $56.22 |
| Novo Nordisk Inc Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $8,046 |
| Novo Nordisk Inc Nov 6, 2025 | Travel and Lodging Wegovy · Obesity · travel to Bowling Green, KY · in-kind | $902 |
| Novo Nordisk Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,654 |
| Novo Nordisk Inc Oct 29, 2025 | Travel and Lodging Wegovy · Obesity · travel to Cincinnati, OH · in-kind | $800 |
| Madrigal Pharmaceuticals Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Oct 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to BLOOMINGTON, IN | $155 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,127 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $568 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $412 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $221 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $32.40 |
| Gilead Sciences, Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4261151;AHM;10004544 | $3,790 |
| Madrigal Pharmaceuticals Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $492 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $232 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $40.00 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $32.79 |
| Intercept Pharmaceuticals, Inc. Jul 15, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $4,960 |
| Intercept Pharmaceuticals, Inc. Jul 15, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Evansville, IN · in-kind | $1,173 |
| Gilead Sciences, Inc. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4116623;AHM;10004544 | $3,790 |
| Gilead Sciences, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4120880;AHM;10004544 | $4,930 |
| Gilead Sciences, Inc. May 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Lexington, KY · in-kind Company’s description;4327987;AHM;10004544 | $737 |
| Ipsen Biopharmaceuticals, Inc May 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,377 |
| Ipsen Biopharmaceuticals, Inc May 12, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,377 |
| Intercept Pharmaceuticals, Inc. Apr 30, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,720 |
| Intercept Pharmaceuticals, Inc. Apr 29, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,720 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $5,580 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $657 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $88.30 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $49.00 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL | $35.00 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $307 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026685;GTF;10004544 | $284 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,836 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $38,803 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.